Halozyme Therapeutics Inc (HALO)vsRevolution Medicines Inc (RVMD)
HALO
Halozyme Therapeutics Inc
$107.20
+0.19%
HEALTHCARE · Cap: $12.29B
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Halozyme Therapeutics Inc generates 224123% more annual revenue ($1.66B vs $742,000). HALO leads profitability with a 24.9% profit margin vs 0.0%. HALO earns a higher WallStSmart Score of 72/100 (B).
HALO
Strong Buy72
out of 100
Grade: B
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 288 in profit
Strong operational efficiency at 59.8%
Revenue surging 47.7% year-over-year
Keeps 25 of every $100 in revenue as profit
Earnings expanding 42.9% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Weak financial health signals
Trading at 85.1x book value
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 24.9% and operating margin at 59.8%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : HALO
The primary concerns for HALO are P/E Ratio, Altman Z-Score, Piotroski F-Score. Debt-to-equity of 14.95 is elevated, increasing financial risk.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
HALO profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
HALO is growing revenue faster at 47.7% — sustainability is the question.
HALO generates stronger free cash flow (237M), providing more financial flexibility.
Bottom Line
HALO scores higher overall (72/100 vs 24/100), backed by strong 24.9% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?